Indication
One indication, assessed end to end.
Scouting a new indication, screening an in-licensing asset, preparing a go / no-go: nine connected modules on one indication, delivered in 10 days.
Decision-grade life-sciences intelligence. In days, not months.
From one indication to your whole pipeline: the epidemiology, treatment landscape, competition, pricing, stakeholders and asset value behind every go / no-go decision – in one evidence-backed, interactive workspace.
Book a 20-minute walkthrough
$9,999 · 10 days · 2–3 KOL and payer interviews
Opportunity assessment has not changed in twenty years. The decisions have.
Three things break when an assessment is conducted.
It arrives too late to matter
A traditional opportunity assessment typically takes two to three months and a six-figure budget. By the time the deck lands, the readout you were waiting for has already happened. BioRev delivers the view you need for a go / no-go call in 10 days, for $9,999.
It is a static deck, and it starts ageing on delivery
You cannot ask a PowerPoint what happens if the diagnosis rate is lower, or if a competitor files a year earlier. And when the portfolio review lands as three hundred slides across fifteen indications, it is out of date before the next allocation discussion. BioRev is an interactive workspace: change the assumption, see the effect on the funnel. Assessment refreshes are available quarterly or on demand.
Fast usually means unverifiable
Quick desk research or a generic AI answer are not reliable for investment decisions. Every BioRev assessment includes 2–3 primary interviews with KOLs and payers, every number is traceable to its source with a stated confidence level, and ex life-science strategy consultants review the output before it reaches you.
One indication, or the whole portfolio.
The same workspace works at two altitudes.
Portfolio
Every indication you hold, compared.
A comparison matrix on the dimensions each assessment measures, a prioritisation map, and a portfolio cockpit for the allocation discussion – kept current with every refresh.
Every indication you assess becomes a row of the portfolio view – whether you start with one or bring the whole pipeline.
What you get
One workspace. Nine connected modules.
Each built to answer one decision question.
Executive Cockpit
Is this opportunity attractive and why?
See in the productEpidemiology
How many patients could actually be addressable?
See in the productTreatment & Unmet Need
How well are patients served today?
See in the productCompetitive Pipeline
Who else is coming to market — and when?
See in the productStakeholder Ecosystem
Who shapes treatment and where are the patients?
See in the productPatient & Physician Intelligence
What problems actually matter to stakeholders?
See in the productPricing & Market Access
What could a therapy in this indication command, and what would payers accept?
See in the productIdeal TPP
What profile would a new asset need to win here?
See in the productAsset Deep Dive
Can the asset win, when can it reach market and what could it be worth?
See in the product
Every assessment ships as an interactive workspace with client login, plus PPT and Excel export.
The same nine modules run on every indication you assess – which is what makes the portfolio view comparable.
The product
See it on Heart Failure.
Every module on Heart Failure, and the portfolio view across ten indications – open and interactive, before you talk to us.
- EpidemiologyPopulation to treatedPrevalent6,700,000Diagnosed5,400,000Treated900,000Open
- Pricing & Market AccessChronic oral archetype, net $/yrLow$3,200Base$4,600High$6,400Open
- Competitive PipelineProgrammes by stagePhase III14Phase II31Phase I22Open
- PortfolioRisk-adjusted peak sales, baseATTR-CM$209mHFrEF$146mCKD$104mOpen
About us
Built by the people who used to do this the old way.
Built by life-sciences strategy professionals who spent years on commercial due diligence, opportunity assessments and asset strategy for pharma and biotech companies – and believed there had to be a better way.